NeuroSense Therapeutics (NRSN) Receivables - Net (2020 - 2023)
NeuroSense Therapeutics (NRSN) posted Receivables - Net of $236000.0 for Q4 2023, down 7.45% sequentially from $255000.0 in Q4 2022, and down 7.45% YoY from $255000.0 in Q4 2022.
NeuroSense Therapeutics (NRSN) Receivables - Net (2020 - 2023) Analysis & Trends
NeuroSense Therapeutics has reported Receivables - Net for 4 years, with the latest figure at $236000.0 in Q4 2023.
- Quarterly Receivables - Net fell 7.45% year-over-year to $236000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $236000.0 (down 7.45% YoY) and the FY2023 annual result came in at $236000.0, down 7.45% from the prior year.
- Receivables - Net slipped to $236000.0 in Q4 2023 per NRSN's latest filing, from $255000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $310000.0 in Q4 2021 and troughed at $30000.0 in Q4 2020.
- A 4-year average of $207750.0 and a median of $245500.0 in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2021 and 2022: Receivables - Net soared 933.33% in 2021, then decreased 17.74% in 2022.
- Over 4 years, Receivables - Net stood at $30000.0 in 2020, then jumped by 933.33% to $310000.0 in 2021, then retreated by 17.74% to $255000.0 in 2022, then declined by 7.45% to $236000.0 in 2023.
- According to Business Quant data, Receivables - Net over the past three periods registered $236000.0, $255000.0, and $310000.0 for Q4 2023, Q4 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2022 | 255,000.00 |
| Dec 31, 2022 | 255,000.00 |
| Dec 31, 2021 | 310,000.00 |
| Dec 31, 2021 | 310,000.00 |
| Dec 31, 2020 | 30,000.00 |
| Dec 31, 2020 | 30,000.00 |